Skip to main content

Advertisement

SpringerLink
Log in

Biosimilars: Clinical Interpretation and Implications for Drug Development

  • Biosimilars (E Mysler, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

The European Medicines Agency’s recent approval of biosimilars and their sudden appearance on the market will revolutionize the way physicians treat the severe conditions for which biologics have had a major impact. In the field of rheumatology, these agents are especially important because most new treatments are based on this kind of medication and because patents on the original drugs are expiring. To use these new medications, the treating physician must read and understand the clinical trials related to biosimilars. These studies are not the typical superiority trials in which new agents are compared with standard treatment; rather, they evaluate different formulas to determine whether they are no better or worse. This article summarizes the clinical aspects of drug development with regard to the efficacy and safety of these new medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pollack A. The New York Times. Published: January 28, 2013. (http://www.nytimes.com/2013/01/29/business/battle-in-states-on-generic-copies-of-biotech-drugs).

  2. Mysler E, Scheinberg. Biosimilars in rheumatology. A view from Latin America. Clin Rheumatol. 2012;31(9):1279–80.

    Article  PubMed  Google Scholar 

  3. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.

    Article  CAS  PubMed  Google Scholar 

  4. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;7:315–8.

    Article  Google Scholar 

  5. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), et al. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product (draft). 2012. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (accessed May 2013).

  6. World Health Organization (WHO). Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf (accessed May 2013).

  7. Guideline on the clinical investigation of the pharmacokinetics of 228 therapeutic proteins (CHMP/EWP/89249/2004).

  8. Expert committee on biological standardization, Geneva, 19 to 23 October 2009 Guidelines on evaluation of similar biotherapeuthic products (SBPs, WHO).

  9. Guideline on the choice of the non-inferiority margin. (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003636.pdf).

  10. Joung J, Robertson JS, Griffiths E, Knezevic I. WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Genebra, 19–20 April 2007. Biologicals. 2008;36(4):269–76.

    Article  CAS  PubMed  Google Scholar 

  11. Laster LL, Johnson MF, Kotler ML. Non-inferiority trial: the at least as good as’ criterion with dichotomous data. Stat Med. 2006;25:1115–30.

    Article  PubMed  Google Scholar 

  12. Dorner T, Strand V, Castaneda-Hernandez G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2013;72:322–8.

    Article  PubMed  Google Scholar 

  13. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121(5):1088–94.

    Article  CAS  PubMed  Google Scholar 

  14. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.

    Article  CAS  PubMed  Google Scholar 

  15. Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis. 2010;69(6):1129–35.

    Article  CAS  PubMed  Google Scholar 

  16. Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210–21.

    Article  CAS  PubMed  Google Scholar 

  17. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60(8):2272–83.

    Article  CAS  PubMed  Google Scholar 

  18. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMA 03 June May 2013 EMEA/CHMP/BMWP/42832/2005 Rev. Committee for Medicinal Products for Human Use (CHMP).

  19. Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs. 2011;71:1527–36.

    Article  CAS  PubMed  Google Scholar 

  20. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins EMEA/CHMP/BMWP/14327/2006.

  21. Guideline on immunogenicity assessment of monoclonal antibodies intended for in-vivo clinical use. EMA/CHMP/BMWP/86289/2010.

  22. Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum. 2012;64(12):3850–5.

    Article  CAS  PubMed  Google Scholar 

  23. WHO Drug Information Vol 23, No. 2, 2009

  24. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24:1720–40.

    Article  CAS  PubMed  Google Scholar 

  25. Lamarque V, Merle L. Generics and substitution modalities: proposed methods for the evaluation of equivalence, traceability and pharmacovigilance reporting. Therapie. 2008;63:311–9.

    Article  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Eduardo Mysler declares no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Organización Médica de Investigación, Buenos Aires, Argentina

    Eduardo Mysler

Authors
  1. Eduardo Mysler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eduardo Mysler.

Additional information

This article is part of the Topical Collection on Biosimilars

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mysler, E. Biosimilars: Clinical Interpretation and Implications for Drug Development. Curr Rheumatol Rep 17, 8 (2015). https://doi.org/10.1007/s11926-014-0483-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-014-0483-y

Keywords

Search

Navigation